Table 1.
Summary of key features across different microglia CreER driver lines in adulthood
| Mouse line | TAM dose | Administration method |
Collection time point (post TAM) |
Brain regions examined |
Specificity | Leakiness | Efficiency | Extraneural recombination | Off-target effects |
Use information | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood | Spleen | Availability | Reference | |||||||||
| Cx3cr1YFP_CreER(Litt) | 10 mg (2x) | oral gavage | P5/P30 | motor CTX | + | +++ | +++ | ++ | +++ | +++ | JAX: 021160 | Parkhurst et al.17 |
| 180 mg/kg (5x) | 4 weeks | motor CTX, STR, HC | ||||||||||
| Cx3cr1CreER(Jung) | 400 mg/kg | subcutaneous | 3 weeks/8 weeks | ehole brain | + | ++ | ++ | ++ | ++ | + | JAX: 020940 | Yona et al.18 |
| 180 mg/kg (5x) | oral gavage | 4 weeks | motor CTX, STR, HC | |||||||||
| P2ry12CreER | 3 mg (3x) | oral gavage | ? | spinal cord, cerebellum, CTX, HC | ++ | + | + | − | + | − | JAX: 034727 | McKinsey et al.8 |
| 180 mg/kg (5x) | 4 weeks | motor CTX, STR, HC | ||||||||||
| Tmem119CreER | 0.2 mg/g (3x) | oral gavage | P3–P10 | somatosensory CTX, STR, HC, thalamus, ChP | ++ | + | + | − | − | − | JAX: 031820 | Kaiser et al.10 |
| 180 mg/kg (5x) | 4 weeks | Motor CTX, STR, HC | ||||||||||
| HexBCreER | 4 mg (2x), 6 mg (3x) | intraperitoneal (i.p.) | P5 | olfactory bulb, CTX, HC, cerebellum, spinal cord | +++ | + | + | +++ | ++ | + | not publicly available | Masuda et al.9 |
| Sall1CreER | 2.5 mg (5x) | i.p. | P0–P14 | CTX, HC, cerebellum, thalamus | + | ++ | + | − | ? | + | not publicly available | Buttgereit et al.15 |